High endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytes

OncoImmunology

Volumn 1, Issue 6, 2012, Pages 829-839

  Martinet, Ludovic ^a,b,c   Le Guellec, Sophie ^c   Filleron, Thomas ^c   Lamant, aurence ^b,d,e   Meyer, Nicolas ^e   Rochaix, Philippe ^c   Garrido, Ignacio ^a,b,c,e   Girard, Jean Philippe ^a,b  

^a INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d CANCER RESEARCH CENTER OF TOULOUSE   (France)

^e TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Blood vessels; Chemokine; Dendritic cells; Immunity; Melanoma; Tumor infiltrating lymphocytes

Indexed keywords

ANTIBODY; CD20 ANTIGEN; CD3 ANTIGEN; CD8 ANTIGEN; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MECA 79; MONOCYTE CHEMOTACTIC PROTEIN 4; RANTES; SECONDARY LYMPHOID TISSUE CHEMOKINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CELL DENSITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DENDRITIC CELL; DISEASE ASSOCIATION; FEMALE; GENE OVEREXPRESSION; HIGH ENDOTHELIAL VENULE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; REGULATORY MECHANISM; STROMA; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION; VENULE;

EID: 84881397413     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20492     Document Type: Article

References (41)

1. MacKie RM, Hauschild A, Eggermont AM. Epidemiology of invasive cutaneous melanoma. Ann Oncol 2009; 20:1-7; PMID:19617292; http://dx.doi.org/10.1093/annonc/mdp252.
2. Disis ML. Immune regulation of cancer. J Clin Oncol 2010; 28:4531-8; PMID:20516428; http://dx.doi.org/10.1200/JCO.2009.27.2146.
3. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis and survival in colorectal cancer. N Engl J Med 2005; 353:2654-66; PMID:16371631; http://dx.doi.org/10.1056/NEJMoa051424.
4. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139.
5. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203-13; PMID:12529460; http://dx.doi.org/10.1056/NEJMoa020177.
6. Fridman WH, Galon J, Pagès F, Tartour E, Sautès-Fridman C, Kroemer G. Prognostic and predictive impact of intra-and peritumoral immune infiltrates. Cancer Res 2011; 71:5601-5; PMID:21846822; http://dx.doi.org/10.1158/0008-5472.CAN-11-1316.
7. Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 2007; 25:869-75; PMID:17327608; http://dx.doi.org/10.1200/JCO.2006.08.9755.
8. Clark WH Jr, Elder DE, Guerry D, 4th, Braitman LE, Trock BJ, Schultz D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989; 81:1893-904; PMID:2593166; http://dx.doi.org/10.1093/jnci/81.24.1893.
9. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77:1303-10; PMID:8608507; http://dx.doi.org/10.1002/(SICI)1097-0142(19960401)77:7<1303::AIDCNCR12>3.0.CO;2-5.
10. Robert C, Thomas L, Bondarenko I, O'Day S, M D JW, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621.
11. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23:2346-57; PMID:15800326; http://dx.doi.org/10.1200/JCO.2005.00.240.
12. Moschos SJ, Edington HD, Land SR, Rao UN, Jukic D, Shipe-Spotloe J, et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006; 24:3164-71; PMID:16809739; http://dx.doi.org/10.1200/JCO.2005.05.2498.
13. Tarhini AA, Kirkwood JM, Gooding WE, Cai C, Agarwala SS. Durable complete responses with highdose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol 2007; 25:3802-7; PMID:17761969; http://dx.doi.org/10.1200/JCO.2006.10.2822.
14. Cipponi A, Wieers G, van Baren N, Coulie PG. Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why? Cancer Immunol Immunother 2011; 60:1153-60; PMID:21553145; http://dx.doi.org/10.1007/s00262-011-1026-2.
15. Girard JP, Springer TA. High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. Immunol Today 1995; 16:449-57; PMID:7546210; http://dx.doi.org/10.1016/0167-5699(95)80023-9.
16. Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 2008; 14:28-36; PMID:18157142; http://dx.doi.org/10.1038/ nm1699.
17. Weishaupt C, Munoz KN, Buzney E, Kupper TS, Fuhlbrigge RC. T-cell distribution and adhesion receptor expression in metastatic melanoma. Clin Cancer Res 2007; 13:2549-56; PMID:17473183; http://dx.doi.org/10.1158/1078-0432.CCR-06-2450.
18. von Andrian UH, Mempel TR. Homing and cellular traffic in lymph nodes. Nat Rev Immunol 2003; 3:867-78; PMID:14668803; http://dx.doi.org/10.1038/nri1222.
19. Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 2006; 6:205-17; PMID:16498451; http://dx.doi.org/10.1038/nri1786.
20. Kobayashi M, Mitoma J, Nakamura N, Katsuyama T, Nakayama J, Fukuda M. Induction of peripheral lymph node addressin in human gastric mucosa infected by Helicobacter pylori. Proc Natl Acad Sci USA 2004; 101:17807-12; PMID:15591109; http://dx.doi.org/10.1073/pnas.0407503101.
21. Martinet L, Garrido I, Filleron T, Le Guellec S, Bellard E, Fournie JJ, et al. Human solid tumors contain high endothelial venules: association with T-and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res 2011; 71:5678-87; PMID:21846823; http://dx.doi.org/10.1158/0008-5472.CAN-11-0431.
22. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199-206; PMID:19917835; http:// dx.doi.org/10.1200/JCO.2009.23.4799.
23. Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol 2012; 13:32-42; PMID:22225723; http://dx.doi.org/10.1016/S1470-2045(11)70155-3.
24. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006; 116:1935-45; PMID:16778987; http://dx.doi.org/10.1172/JCI27745.
25. Moussion C, Girard JP. Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules. Nature 2011; 479:542-6; PMID:22080953; http://dx.doi.org/10.1038/nature10540.
26. Oble DA, Loewe R, Yu P, Mihm MC Jr. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun 2009; 9:3; PMID:19338264.
27. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29:235-71; PMID:21219185; http://dx.doi.org/10.1146/annurevimmunol-031210-101324.
28. Lowes MA, Bishop GA, Crotty K, Barnetson RS, Halliday GM. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J Invest Dermatol 1997; 108:914-9; PMID:9182821; http://dx.doi.org/10.1111/1523-747.ep12292705.
29. Wagner SN, Schultewolter T, Wagner C, Briedigkeit L, Becker JC, Kwasnicka HM, et al. Immune response against human primary malignant melanoma: a distinct cytokine mRNA profile associated with spontaneous regression. Lab Invest 1998; 78:541-50; PMID:9605179.
30. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6:295-307; PMID:16557261; http://dx.doi.org/10.1038/nri1806. 31. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24:5373-80; PMID:17135638; http://dx.doi.org/10.1200/JCO.2006.05.9584.
31. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24:5373-80; PMID:17135638; http://dx.doi.org/10.1200/JCO.2006.05.9584
32. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9; PMID:15322536; http://dx.doi.org/10.1038/nm1093.
33. de Chaisemartin L, Goc J, Damotte D, Validire P, Magdeleinat P, Alifano M, et al. Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res 2011; 71:6391-9; PMID:21900403; http://dx.doi.org/10.1158/0008-5472.CAN-11-0952.
34. Thompson ED, Enriquez HL, Fu YX, Engelhard VH. Tumor masses support naive T cell infiltration, activation and differentiation into effectors. J Exp Med 2010; 207:1791-804; PMID:20660615; http://dx.doi.org/10.1084/jem.20092454.
35. Schrama D, thor Straten P, Fischer WH, McLellan AD, Bröcker EB, Reisfeld RA, et al. Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity 2001; 14:111-21; PMID:11239444; http://dx.doi.org/10.1016/S1074-7613(01)00094-2.
36. Yu P, Lee Y, Liu W, Chin RK, Wang J, Wang Y, et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 2004; 5:141-9; PMID:14704792; http://dx.doi.org/10.1038/ni1029.
37. Yu P, Lee Y, Wang Y, Liu X, Auh S, Gajewski TF, et al. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol 2007; 179:1960-8; PMID:17641063.
38. Spiotto MT, Yu P, Rowley DA, Nishimura MI, Meredith SC, Gajewski TF, et al. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 2002; 17:737-47; PMID:12479820; http://dx.doi.org/10.1016/S1074-7613(02)00480-6.
39. Bai XF, Liu J, Li O, Zheng P, Liu Y. Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes. J Clin Invest 2003; 111:1487-96; PMID:12750398.
40. Eggermont AM. Immunotherapy: Vaccine trials in melanoma-time for reflection. Nat Rev Clin Oncol 2009; 6:256-8; PMID:19390551; http://dx.doi.org/10.1038/nrclinonc.2009.42.
41. Chen Q, Wang WC, Evans SS. Tumor microvasculature as a barrier to antitumor immunity. Cancer Immunol Immunother 2003; 52:670-9; PMID:12920482; http://dx.doi.org/10.1007/s00262-003-0425-4.